Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
4D Molecular Therapeutics
Biotech
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka, securing $85 million in cash to fund the asset’s phase 3 development.
James Waldron
Oct 31, 2025 5:09am
4DMT climbs as gene therapy patients keep jettisoning jabs
Aug 1, 2025 5:35am
4DMT lays off 25% of workforce while phase 3 timeline ramps up
Jul 3, 2025 4:52am
4DMT restructures pipeline, extending cash runway through 2028
Jan 10, 2025 2:00pm
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
Adverum's gene therapy reduces treatment burden in wet AMD
Feb 8, 2024 11:17am
